Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies. The news flow around MiNK centers on its progress in oncology, graft-versus-host disease (GvHD), transplantation, and severe pulmonary inflammatory disease, reflecting the company’s focus on immune reconstitution and immune modulation.
News updates commonly highlight clinical trial milestones for its lead iNKT therapy agenT-797, including Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. MiNK also reports on preclinical and translational data for next-generation programs such as MiNK-215, an IL-15–enhanced, FAP-targeting CAR-iNKT therapy designed to remodel the tumor stroma and enhance anti-tumor immunity.
Investors following INKT news can expect coverage of peer-reviewed publications, late-breaking presentations at scientific meetings, grant awards from agencies such as NIH and the Department of Defense, and philanthropic funding supporting GvHD and transplant-related studies. Corporate news items also include quarterly financial results, at-the-market equity program updates, and leadership and board appointments that the company associates with advancing its iNKT platform toward pivotal development.
This news page aggregates MiNK Therapeutics’ press releases and related market-moving announcements in one place, making it easier to track clinical data readouts, regulatory and funding developments, and strategic initiatives involving its allogeneic iNKT cell therapy pipeline.
MiNK Therapeutics (NASDAQ: INKT) is advancing its allogeneic invariant natural killer T (iNKT) cell therapies, particularly AgenT-797, in ongoing clinical trials for solid tumors and COVID-19 related ARDS, showing a remarkable 75% survival rate in treated patients. No lymphodepletion or serious side effects such as cytokine release syndrome have been reported. The company completed a $46 million IPO and recorded a cash burn of approximately $13 million in 2021, with a cash balance of $39 million as of year-end. MiNK plans to manufacture over 10,000 doses of iNKT cells annually to support its clinical programs.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its fourth quarter and full year 2021 financial results and business update on March 18, 2022. The company specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The financial report will be accessible via a press release and the investor section of the company's website. MiNK's pipeline includes native and engineered iNKT programs aimed at scalable manufacturing and off-the-shelf delivery.
MiNK Therapeutics has initiated a Phase 1 clinical trial for AgenT-797, targeting patients with solid tumor cancers. The therapy can be dosed up to 1 billion cells without lymphodepletion, showing no signs of cytokine release syndrome or neurotoxicity. Clinical trials are also being conducted for multiple myeloma and viral ARDS. Preliminary results indicate a favorable safety profile and promising early clinical activity, especially when combined with approved anti-PD-1 checkpoint inhibitors. The company is focused on developing allogeneic iNKT cell therapies for cancer treatment.
MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27, 2022, at 12:00 PM ET. The event will discuss the company's advancements in iNKT cell therapies aimed at treating cancer and immune-mediated diseases. Investors can access the live presentation and a replay through MiNK's website after the event.
MiNK is focused on developing scalable iNKT cell therapies, enhancing treatment options in oncology.
MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat hosted by Evercore on December 1, 2021, at 8:25 AM ET. This event will focus on the company's innovative allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases. Interested parties can register for the event online, and a replay will be available afterward on the MiNK website.
For further details about MiNK Therapeutics and its clinical-stage developments, visit their official website.
MiNK Therapeutics announced preliminary survival data from its phase 1 study of agenT-797, an iNKT cell therapy for COVID-19 patients experiencing respiratory distress. The therapy achieved a 77% survival rate among older, ventilated patients, significantly higher than the national average of 20-30%. Additional findings showcased evidence of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma patients. The company plans to expand its clinical programs, including trials for solid tumors cleared by the FDA.
MiNK Therapeutics announced new data presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing the potential of its iNKT cell therapies, particularly agenT-797. The data emphasize anti-tumor activity, tissue distribution, and the engineered iNKT cells' capabilities against solid and liquid tumors. Presentations will cover three abstracts, detailing clinical persistence and preclinical efficacy. The full text of the abstracts will be available on November 9, ahead of the investor section release on November 12.
MiNK Therapeutics has successfully closed its initial public offering of 3,333,334 shares of common stock at a price of $12.00 per share, generating gross proceeds of approximately $40 million. The shares began trading on the Nasdaq Global Market under the ticker symbol INKT on October 15, 2021. The offering was managed by Evercore ISI and William Blair, with co-managers B. Riley and Baird. This funding will support the company’s efforts to develop its pioneering iNKT cell therapies for cancer and immune-mediated diseases.
MiNK Therapeutics, a clinical stage biotechnology firm, announced its initial public offering (IPO) of 3,333,334 shares at $12.00 each, aiming for gross proceeds of approximately $40 million. Trading is set to begin on Nasdaq under the ticker symbol INKT on October 15, 2021, with the offering closing around October 19, 2021. The underwriters are granted an option to buy an additional 500,000 shares. The IPO proceeds will support the development of allogeneic iNKT therapies for cancer and immune-mediated diseases.
MiNK Therapeutics, a biopharmaceutical company focused on iNKT cell therapies for cancer and immune diseases, has announced the acceptance of three abstracts for the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. The presentations will cover AgenT-797, including its persistence, tissue distribution, and anti-tumor activity. Abstracts will be released on November 9, 2021, with data also available on the investor section of their website post-presentation on November 12, 2021.